E-cigarettes May Help Adults Switch From Cigarettes but Encourage Smoking in Teens

(February 1, 2018)

By AMERICAN HEART ASSOCIATION NEWS CancerConnect News: E-cigarettes can be highly addictive, and kids who use them are more likely to start smoking regular cigarettes, concluded a panel of public health experts. A report released this week by the National... Continue Reading


Roswell Park Research Identifies Link between Smoking, Sex Hormones and Lung Cancer

(January 29, 2018)

CancerConnect News:  The risk of developing non-small cell lung cancer (NSCLC) is higher for women and smokers according to the results of a recent study published by a team of doctors led by Christine Ambrosone, PhD, Chair of Cancer Prevention and Control... Continue Reading


FDA Broadens Gilotrif Indication to Previously Untreated, Metastatic NSCLC with Other Non-Resistant EGFR Mutations

(January 24, 2018)

CancerConnect News: The Food and Drug Administration (FDA) has granted approval to Gilotrif®  (afatinib) for a broadened indication in first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant... Continue Reading


Keytruda in Combination with Alimta and Platinum Chemotherapy Improves Survival in Non Small Cell Lung Cancer

(January 17, 2018)

CancerConnect News: Keytruda (pembrolizumab) is the first PD1 Inhibitor to demonstrate improved overall survival when combined with chemotherapy as primary treatment for metastatic non-squamous non-small cell lung cancer (NSCLC). The KEYNOTE-189 clinical... Continue Reading


Tagrisso Improves Progression-free Survival in Asian EGFR-mutated Lung Cancer Patients

(January 15, 2018)

CancerConnect News: Tagrisso (osimertinib) improves progression-free survival compared to standard first line therapy in Asian patients with epidermal growth factor receptor (EGFR)-mutated non-small-cell lung cancer (NSCLC). 1,2 Lung cancer is the number... Continue Reading


Ulixertinib A First-in-class ERK Inhibitor Shows Early Efficacy in Patients With Advanced Cancers

(January 8, 2018)

CancerConnect News: The novel ERK1/2 kinase inhibitor ulixertinib displayed an acceptable safety profile and had clinical activity in patients whose cancers had mutations in the MAPK cell-signaling pathway, according to data from a recent phase 1 clinical... Continue Reading


First Line Combination Therapy Improves Progression-Free Survival In Advanced Lung Cancer

(January 8, 2018)

A recently reported study confirms that combination therapy using the “checkpoint inhibitor” Tecentriq® (atezolizumab) and chemotherapy as first line treatment for advanced non-squamous non-small-cell lung cancer (NSCLC) improves progression-free... Continue Reading


Start 2018 Right: Plan for Cancer Screening and Save Lives!

(January 5, 2018)

Screening guidelines should initiate conversations with your healthcare team.  Charles H Weaver MD, Editor CancerConnect CancerConnect News: The goal of cancer screening is to find disease at early stages in people who are otherwise asymptomatic—before... Continue Reading


The Role of Immunotherapy in the Treatment of Advanced Non Small Cell Lung Cancer

(December 6, 2017)

Treatment options for advanced NSCLC fit into 3 main categories… Targeted Therapy – we test lung cancer for specific mutations to see if we have an appropriate targeted medication. Immunotherapy – if targeted therapy is not an option immunotherapy... Continue Reading


Imfinzi Improves Survival in Stage 3 Non Small Cell Lung Cancer

(October 17, 2017)

Immunotherapy could be the new standard of care in patients with non-small cell lung cancer (NSCLC).  The novel immunotherapy checkpoint inhibitors Keytruda® (pembrolizumab) and Opdivo (nivolumab) are already standard of care for advanced NSCLC.1   A... Continue Reading


Latest Lung Cancer News By Stage


General Lung Cancer

Many Late Stage Lung Cancer Patients do not Receive Treatment

(January 24, 2017)

A national study by researchers at UC Davis Comprehensive Cancer Center has found that a significant number of lung cancer patients are not receiving treatment. Based on data between 1998 and 2012 from the National Cancer Database, 21 percent of patients... Continue Reading


Keytruda® Active in Small Cell Lung Cancer

(December 27, 2016)

Recently updated findings from the phase 1b KEYNOTE-028 study investigating the use of Keytruda® (pembrolizumab) in small cell lung cancer (SCLC) were recently presented at the 17th World Conference on Lung Cancer. Lung cancer remains the leading cause... Continue Reading


Tagrisso®: New Standard of Care for Certain Lung Cancer

(December 19, 2016)

Treatment with the targeted agent Tagrisso (osimertinib) significantly delayed cancer progression, and resulted in fewer side effects, than standard chemotherapy for patients with advanced non-small cell lung cancer (NSCLC) whose cancer had progressed... Continue Reading


Personalized Lung Cancer Care & Precision Medicine

(November 8, 2016)

Targeted and more-individualized treatment for NSCLC becomes a reality. Lung cancers used to be diagnosed solely by a visual microscopic examination of tumor tissue and all patients received the same chemotherapy. Now, doctors are personalizing care by... Continue Reading


Precision Medicine Guides NSCLC Cancer Treatment: All Patients Should Undergo Molecular Testing

(October 27, 2016)

Lung cancer remains the leading cause of cancer-related deaths worldwide. In the United States, non-small cell lung cancer (NSCLC) accounts for 75–80% of all lung cancers. Although progress has been made in recent years, the majority of patients with... Continue Reading


More General Lung Cancer